stockrowAscendis Pharma A/S
ASND Healthcare Biotechnology
Ascendis Pharma A/S’s revenue for fiscal 2025 (year ended December 2025) was $814.8 million, up 107.1% from fiscal 2024.
- Revenue
- +119.9%
- EPS
- +612.3%
- Free cash flow
- +2,335.9%
- Total debt
- −41.8%
Quarter to June 2026, against a year earlier
Follow ASND
Alert me
Ascendis Pharma A/S (ASND) EV/FCF
As of 5 November 2026, Ascendis Pharma A/S (ASND) trades at a EV/FCF of 41.1×. Over the past ten years it has ranged from −115× (December 2025) to 339× (June 2026); the current reading is higher than 95% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 257× | — |
| FY2024 | −25.0× | — |
| FY2023 | −14.4× | — |
| FY2022 | −12.4× | — |
| FY2021 | −12.8× | — |
| FY2020 | −23.5× | — |
| FY2019 | −28.8× | — |
| FY2018 | −13.4× | — |
| FY2017 | −10.3× | — |
| FY2016 | −4.9× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Jun 2026 | 43.2× | (85.35%) |
| Mar 2026 | 295× | 14.65% |
| Dec 2025 | 257× | — |
| Sep 2025 | −104× | — |
| 42 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| BBIO BridgeBio Pharma, Inc. compare | −39.7× |
| INSM Insmed, Inc. compare | −37.2× |
| SMMT Summit Therapeutics PLC compare | −23.1× |
| BNTX BioNTech SE Sponsored ADR compare | −9.6× |
| EXEL Exelixis, Inc. compare | 14.1× |
| HALO Halozyme Therapeutics, Inc. compare | 18.4× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 22.9× |
| JAZZ Jazz Pharmaceuticals PLC compare | 26.2× |
| ASND Ascendis Pharma A/S | 41.1× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on ASND
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement